Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DUMAS dual thrombolytic therapy for acute ischemic stroke
NL-OMON55848Phase 2Recruiting
- Sponsor
- Erasmus MC
- Start
- Aug 2019
- Modality
- Recombinant Proteins and Enzymes, Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of mutant pro-urokinase and tissue-plasminogen activator in ischemic stroke and brain infarction (2 arms), sponsored by Erasmus MC. Primary endpoint: Any post-intervention intracranial hemorrhage. Started Aug 2019; status: recruiting.
02
Drugs
mutant pro-urokinasetissue-plasminogen activator
03
Conditions
ischemic strokebrain infarction
Beyond the preview
Go deeper on NL-OMON55848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55848.